Legend Biotech Announces Annual General Meeting for June 2025

Legend Biotech ( (LEGN) ) has shared an update.

Legend Biotech Corporation announced its Annual General Meeting of Shareholders scheduled for June 12, 2025, at its Somerset, New Jersey office. The meeting will cover several key proposals, including the reception of audited financial statements for 2024, the re-appointment of Ernst & Young LLP as the independent auditor, and the re-election of directors Dr. Patrick Casey, Yau Wai Man Philip, and Dr. Fangliang Zhang. These decisions are crucial for the company’s governance and operational continuity, impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s strong revenue growth and positive earnings call developments are offset by ongoing profitability and cash flow challenges. Technical indicators suggest possible resistance, and valuation remains difficult with negative earnings. The company’s ambitious expansion plans and pipeline developments add potential, but financial stability and operational execution are critical for future success.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation operates in the biotechnology industry, focusing on the development and commercialization of novel therapies for oncology and other serious diseases. The company is known for its innovative approaches in cell therapy and has a market focus on addressing unmet medical needs.

Average Trading Volume: 1,337,403

Technical Sentiment Signal: Sell

Current Market Cap: $5.84B

See more data about LEGN stock on TipRanks’ Stock Analysis page.